PURPOSE: To determine the maximum tolerated dose per day of silybin phosphatidylcholine (Siliphos) in patients with advanced hepatocellular carcinoma (HCC) and hepatic dysfunction. EXPERIMENTAL DESIGN:Patients with advanced HCC not eligible for other therapies based on poor hepatic function were enrolled in a phase I study of silybin phosphatidylcholine. A standard phase I design was used with 4 planned cohorts, dose escalating from 2, 4, 8, to 12 g per day in divided doses for 12 weeks. RESULTS: Three participants enrolled in this single institution trial. All enrolled subjects consumed 2 g per day of study agent in divided doses. Serum concentrations of silibinin and silibininglucuronide increased within 1 to 3 weeks. In all 3 patients, liver function abnormalities and tumor marker α-fetoprotein progressed, but after day 56 the third patient showed some improvement in liver function abnormalities and inflammatory biomarkers. All 3 participants died within 23 to 69 days of enrolling into the trial, likely from hepatic failure, but it could not be ruled out that deaths were possibly due to the study drug. CONCLUSION: Short-term administration of silybin phosphatidylcholine in patients with advanced HCC resulted in detectable increases in silibinin and its metabolite, silibinin glucuronide. The maximum tolerated dose could not be established. Since patients died soon after enrollment, this patient population may have been too ill to benefit from an intervention designed to improve liver function tests.
RCT Entities:
PURPOSE: To determine the maximum tolerated dose per day of silybin phosphatidylcholine (Siliphos) in patients with advanced hepatocellular carcinoma (HCC) and hepatic dysfunction. EXPERIMENTAL DESIGN:Patients with advanced HCC not eligible for other therapies based on poor hepatic function were enrolled in a phase I study of silybin phosphatidylcholine. A standard phase I design was used with 4 planned cohorts, dose escalating from 2, 4, 8, to 12 g per day in divided doses for 12 weeks. RESULTS: Three participants enrolled in this single institution trial. All enrolled subjects consumed 2 g per day of study agent in divided doses. Serum concentrations of silibinin and silibinin glucuronide increased within 1 to 3 weeks. In all 3patients, liver function abnormalities and tumor marker α-fetoprotein progressed, but after day 56 the third patient showed some improvement in liver function abnormalities and inflammatory biomarkers. All 3participants died within 23 to 69 days of enrolling into the trial, likely from hepatic failure, but it could not be ruled out that deaths were possibly due to the study drug. CONCLUSION: Short-term administration of silybin phosphatidylcholine in patients with advanced HCC resulted in detectable increases in silibinin and its metabolite, silibinin glucuronide. The maximum tolerated dose could not be established. Since patients died soon after enrollment, this patient population may have been too ill to benefit from an intervention designed to improve liver function tests.
Authors: A Hollebecque; S Cattan; O Romano; G Sergent; A Mourad; A Louvet; S Dharancy; E Boleslawski; S Truant; F-R Pruvot; M Hebbar; O Ernst; P Mathurin Journal: Aliment Pharmacol Ther Date: 2011-09-29 Impact factor: 8.171
Authors: Ales Vidlar; Jitka Vostalova; Jitka Ulrichova; Vladimir Student; Milan Krajicek; Jana Vrbkova; Vilim Simanek Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2010-09 Impact factor: 1.245
Authors: Nancy Heffernan; David Cella; Kimberly Webster; Linda Odom; Mary Martone; Steven Passik; Marilyn Bookbinder; Yuman Fong; William Jarnagin; Leslie Blumgart Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: R Lencioni; M Kudo; S-L Ye; J-P Bronowicki; X-P Chen; L Dagher; J Furuse; J F Geschwind; L Ladrón de Guevara; L L de Guevara; C Papandreou; A J Sanyal; T Takayama; S K Yoon; K Nakajima; F Cihon; S Heldner; J A Marrero Journal: Int J Clin Pract Date: 2012-07 Impact factor: 2.503
Authors: Thomas W Flaig; Daniel L Gustafson; Lih-Jen Su; Joseph A Zirrolli; Frances Crighton; Gail S Harrison; A Scott Pierson; Rajesh Agarwal; L Michael Glodé Journal: Invest New Drugs Date: 2006-11-01 Impact factor: 3.850
Authors: Roy L Hawke; Sarah J Schrieber; Tedi A Soule; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Josh Berman; Qi-Ying Liu; Edward Doo; Michael W Fried Journal: J Clin Pharmacol Date: 2009-10-19 Impact factor: 3.126
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Rikki A M Brown; Kirsty L Richardson; Tasnuva D Kabir; Debbie Trinder; Ruth Ganss; Peter J Leedman Journal: Front Oncol Date: 2020-04-09 Impact factor: 6.244